Classification of chronic myeloid disorders

From Dameshek towards a semi-molecular system

Ayalew Tefferi, Gary Gilliland

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Hematological malignancies are phenotypically organized into lymphoid and myeloid disorders, although such a distinction might not be precise from the standpoint of lineage clonality. In turn, myeloid malignancies are broadly categorized into either acute myeloid leukemia (AML) or chronic myeloid disorder (CMD), depending on the presence or absence, respectively, of AML-defining cytomorphologic and cytogenetic features. The CMD are traditionally classified by their morphologic appearances into discrete clinicopathologic entities based primarily on subjective technologies. It has now become evident that most CMD represent clonal stem cell processes where the primary oncogenic event has been characterized in certain instances; Bcr/Abl in chronic myeloid leukemia, FIP1L1-PDGFRA or c-kitD816V in systemic mastocytosis, rearrangements of PDGFRB in chronic eosinophilic leukemia, and rearrangements of FGFR1 in stem cell leukemia/lymphoma syndrome. In addition, Bcr/Abl-negative classic myeloproliferative disorders are characterized by recurrent JAK2V617F mutations, whereas other mutations affecting the RAS signaling pathway molecules have been associated with juvenile myelomonocytic leukemia. Such progress is paving the way for a transition from a histologic to a semi-molecular classification system that preserves conventional terminology, while incorporating new information on molecular pathogenesis.

Original languageEnglish (US)
Pages (from-to)365-385
Number of pages21
JournalBest Practice and Research: Clinical Haematology
Volume19
Issue number3
DOIs
StatePublished - Sep 2006

Fingerprint

Stem cells
Acute Myeloid Leukemia
Stem Cells
Juvenile Myelomonocytic Leukemia
Systemic Mastocytosis
Platelet-Derived Growth Factor beta Receptor
Myeloproliferative Disorders
Mutation
Hematologic Neoplasms
Terminology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Lymphoma
Leukemia
Technology
Molecules
Neoplasms
Pdgfra-Associated Chronic Eosinophilic Leukemia

Keywords

  • acute myeloid leukemia
  • Bcr/Abl
  • chronic myeloid disorder

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Classification of chronic myeloid disorders : From Dameshek towards a semi-molecular system. / Tefferi, Ayalew; Gilliland, Gary.

In: Best Practice and Research: Clinical Haematology, Vol. 19, No. 3, 09.2006, p. 365-385.

Research output: Contribution to journalArticle

@article{6286ca10653e420ab319f19ff196f603,
title = "Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system",
abstract = "Hematological malignancies are phenotypically organized into lymphoid and myeloid disorders, although such a distinction might not be precise from the standpoint of lineage clonality. In turn, myeloid malignancies are broadly categorized into either acute myeloid leukemia (AML) or chronic myeloid disorder (CMD), depending on the presence or absence, respectively, of AML-defining cytomorphologic and cytogenetic features. The CMD are traditionally classified by their morphologic appearances into discrete clinicopathologic entities based primarily on subjective technologies. It has now become evident that most CMD represent clonal stem cell processes where the primary oncogenic event has been characterized in certain instances; Bcr/Abl in chronic myeloid leukemia, FIP1L1-PDGFRA or c-kitD816V in systemic mastocytosis, rearrangements of PDGFRB in chronic eosinophilic leukemia, and rearrangements of FGFR1 in stem cell leukemia/lymphoma syndrome. In addition, Bcr/Abl-negative classic myeloproliferative disorders are characterized by recurrent JAK2V617F mutations, whereas other mutations affecting the RAS signaling pathway molecules have been associated with juvenile myelomonocytic leukemia. Such progress is paving the way for a transition from a histologic to a semi-molecular classification system that preserves conventional terminology, while incorporating new information on molecular pathogenesis.",
keywords = "acute myeloid leukemia, Bcr/Abl, chronic myeloid disorder",
author = "Ayalew Tefferi and Gary Gilliland",
year = "2006",
month = "9",
doi = "10.1016/j.beha.2005.07.001",
language = "English (US)",
volume = "19",
pages = "365--385",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Classification of chronic myeloid disorders

T2 - From Dameshek towards a semi-molecular system

AU - Tefferi, Ayalew

AU - Gilliland, Gary

PY - 2006/9

Y1 - 2006/9

N2 - Hematological malignancies are phenotypically organized into lymphoid and myeloid disorders, although such a distinction might not be precise from the standpoint of lineage clonality. In turn, myeloid malignancies are broadly categorized into either acute myeloid leukemia (AML) or chronic myeloid disorder (CMD), depending on the presence or absence, respectively, of AML-defining cytomorphologic and cytogenetic features. The CMD are traditionally classified by their morphologic appearances into discrete clinicopathologic entities based primarily on subjective technologies. It has now become evident that most CMD represent clonal stem cell processes where the primary oncogenic event has been characterized in certain instances; Bcr/Abl in chronic myeloid leukemia, FIP1L1-PDGFRA or c-kitD816V in systemic mastocytosis, rearrangements of PDGFRB in chronic eosinophilic leukemia, and rearrangements of FGFR1 in stem cell leukemia/lymphoma syndrome. In addition, Bcr/Abl-negative classic myeloproliferative disorders are characterized by recurrent JAK2V617F mutations, whereas other mutations affecting the RAS signaling pathway molecules have been associated with juvenile myelomonocytic leukemia. Such progress is paving the way for a transition from a histologic to a semi-molecular classification system that preserves conventional terminology, while incorporating new information on molecular pathogenesis.

AB - Hematological malignancies are phenotypically organized into lymphoid and myeloid disorders, although such a distinction might not be precise from the standpoint of lineage clonality. In turn, myeloid malignancies are broadly categorized into either acute myeloid leukemia (AML) or chronic myeloid disorder (CMD), depending on the presence or absence, respectively, of AML-defining cytomorphologic and cytogenetic features. The CMD are traditionally classified by their morphologic appearances into discrete clinicopathologic entities based primarily on subjective technologies. It has now become evident that most CMD represent clonal stem cell processes where the primary oncogenic event has been characterized in certain instances; Bcr/Abl in chronic myeloid leukemia, FIP1L1-PDGFRA or c-kitD816V in systemic mastocytosis, rearrangements of PDGFRB in chronic eosinophilic leukemia, and rearrangements of FGFR1 in stem cell leukemia/lymphoma syndrome. In addition, Bcr/Abl-negative classic myeloproliferative disorders are characterized by recurrent JAK2V617F mutations, whereas other mutations affecting the RAS signaling pathway molecules have been associated with juvenile myelomonocytic leukemia. Such progress is paving the way for a transition from a histologic to a semi-molecular classification system that preserves conventional terminology, while incorporating new information on molecular pathogenesis.

KW - acute myeloid leukemia

KW - Bcr/Abl

KW - chronic myeloid disorder

UR - http://www.scopus.com/inward/record.url?scp=33744999628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744999628&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2005.07.001

DO - 10.1016/j.beha.2005.07.001

M3 - Article

VL - 19

SP - 365

EP - 385

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 3

ER -